drugset / Trial / NCT00859729
Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer
Phase 1/2
Completed
15 enrolled
Uppsala University
Cyto Pulse Sciences, Inc. · collabKarolinska Institutet · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the feasibility and safety of vaccination with increasing doses of xenogenic DNA administered intradermally in combination with electroporation in patients with relapse of prostate cancer. The DNA encodes prostate specific antigen (PSA) from Rhesus Macaque (Macaca mulatta), a protein that is 89% homologous to human PSA. The study will also assess the safety and functionality of the DERMA VAX™ (Cyto Pulse Sciences) DNA vaccine delivery system.
Timeline
- Start
- 2008-12
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pVAXrcPSAv53l | Vaccine | 50 ug | Other |
| Subject | pVAXrcPSAv53l | Vaccine | 150 ug | Other |
| Subject | pVAXrcPSAv53l | Vaccine | 400 ug | Other |
| Subject | pVAXrcPSAv53l | Vaccine | 1000 ug | Other |